Pulmonx Corp
NASDAQ:LUNG
Pulmonx Corp
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
Pulmonx Corp. engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 253 full-time employees. The company went IPO on 2020-10-01. The firm provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The Company’s solutions include Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System and StratX Lung Analysis Platform, which is designed to treat severe emphysema patients. Its solution provides bronchoscopic lung volume reduction without surgery. The Zephyr Valves are indicated for bronchoscopic treatment of adult patients with hyperinflation associated with severe emphysema in regions of the lung that have little to no collateral ventilation. The Zephyr Valves are placed in the airways to occlude the diseased parts of the lung, allowing trapped air to escape.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
